Alzai Health Corp. Announces IPO of up to 10M Units at $0.40 Each

Why It Matters

The capital raise equips Alzai to scale its AI Alzheimer’s screening platform, addressing a critical gap in early diagnosis and signaling strong investor appetite for health‑tech IPOs on Canadian exchanges.

Key Takeaways

• Offering 8‑10 M units at $0.40 CAD (~$0.30 USD) each.
• Units include common share plus half warrant exercisable at $0.60 CAD (~$0.44 USD).
• Expected gross proceeds $3.2‑4 M CAD (~$2.4‑3 M USD).
• Closing targeted for May 21 2026; TSXV ticker “ALZI”.
• Funds will fuel AI Alzheimer’s screening R&D and market expansion.

Pulse Analysis

Alzai Health Corp. is positioning itself at the intersection of artificial intelligence and neuro‑degenerative disease detection, a market projected to exceed $15 billion globally as the aging population expands. Its non‑invasive risk‑screening solution leverages existing clinical data to flag early cognitive decline, potentially shifting Alzheimer’s diagnosis from a reactive to a proactive model. By shortening the time to identification, Alzai not only improves patient outcomes but also reduces downstream healthcare costs, a compelling value proposition for payors and providers alike.

The decision to list on the TSX Venture Exchange reflects a broader trend of Canadian capital markets courting health‑tech innovators. The 8‑10 million‑unit offering, priced at roughly $0.30 USD per unit, aligns with recent micro‑cap biotech IPOs that have attracted both institutional and retail investors seeking exposure to high‑growth, data‑driven therapeutics. The inclusion of warrants provides additional upside, while the modest 7 % agent commission—reduced for president’s‑list investors—keeps dilution in check. Compared with U.S. listings, the Canadian route offers a faster regulatory timeline and lower compliance costs, making it an attractive launchpad for companies still building clinical evidence.

With an estimated $2.4‑3 million USD in proceeds, Alzai plans to accelerate product development, expand its sales force, and deepen partnerships with healthcare systems. The infusion will fund algorithm refinement, clinical validation studies, and market entry initiatives across North America. While the IPO supplies needed runway, the company must navigate competitive pressures from larger diagnostics firms and secure reimbursement pathways. Successful execution could establish Alzai as a leader in AI‑enabled early Alzheimer’s detection, driving both shareholder value and broader public‑health benefits.

Deal Summary

Alzai Health Corp. filed its final prospectus for an initial public offering of 8‑10 million units at $0.40 per unit, targeting gross proceeds of $3.2 million to $4.0 million. Haywood Securities Inc. will act as the exclusive underwriter, with the offering expected to close around May 21, 2026.